Pantarhei Bioscience BV (PRB) is a limited liability company (‘Besloten Vennootschap’) located in the Netherlands focussing on the development of new treatments for Woman’s Health and endocrine cancer applications.
The product pipeline is based on Pantarhei’s ability to identify novel medical uses of existing molecules, drugs, hormones, biologicals or combinations thereof in these areas of medicine. The main areas of expertise of PRB are reproductive hormone related treatments and diseases such as contraception and menopausal hormone therapy.
PRB has founded its subsidiary company – Pantarhei Oncology BV (PRO) – to develop treatments for oncology indications. The main areas of expertise of PRO are breast cancer, prostate cancer and ovarian cancer.
The business model of PRB is based on creating intellectual property (IP) for new treatment concepts and providing in-house project management. All research and development activities are outsourced. PRB develops patent protected new treatments up to proven efficacy and safety (proof-of-concept) in the human (phase II). Using existing molecules often provides first evidence of safety. After successful proof-of-concept, data and IP are sold or licensed-out to a licensee or (pharmaceutical) partner for final development (phase III), regulatory approval and commercialisation.